UK Reforms to Clinical Trials: Getting Patients Cutting-Edge Treatments Sooner

The UK is stepping up its game in medical research. In January 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) announced a new round of reforms designed to make the country a more efficient and attractive place to run clinical trials, delivering clear benefits for patients, researchers, and the life sciences sector.

What's Changing?

1. Faster Trial Setup and Approvals

The UK has seen a meaningful increase in clinical trial applications – a 9% rise in 2025 compared with the previous year – particularly in early-stage and first-in-human (FIH) studies.

Under the forthcoming regulations (due to come into force April 2026), around one in five studies is expected to benefit from a new fast-track notification route. This will allow lower-risk trials to begin more quickly, reducing unnecessary regulatory burden while maintaining high safety standards. There is also a 14-day assessment pathway for Phase I (FIH) trials, making the UK more attractive to global developers.

2. Modern, Agile Regulation

The MHRA's new framework will lean into modern research methods, including making use of early overseas safety data that meets UK standards, and assessing computer model simulations (such as in silico trials) to predict how medicines might behave before patient testing begins. These changes aim to reflect how cutting-edge medicines are developed today while ensuring patient safety remains at the forefront.

3. Better Support for Researchers

The 75% rise in scientific advice meetings shows that industry is engaging with regulators earlier in the process, supporting successful trial designs first time and helping to avoid delays. Participation rates in research are also increasing, with more than 450,000 people in England taking part in studies last year, demonstrating both patient interest and the growing role clinical research plays in improving care.

Why Does It Matter?

These reforms are part of a broader strategy – including the government's 10-Year Health Plan – to transform the UK into a global leader for life sciences innovation. Shorter timelines and more predictable processes mean patients can access innovative therapies sooner, potentially improving outcomes for serious or complex conditions. Researchers and companies gain confidence in planning studies in the UK, and investment and economic growth in the life sciences sector are encouraged, strengthening the UK's global research profile.

What Comes Next for Clinical Trials in the UK?

The MHRA's reforms build on years of progress, including faster approval times in recent years and closer collaboration with ethics bodies. When the new clinical trial regulations take effect later in 2026, the UK is set to have one of the most flexible and efficient clinical research systems in the world. For patients, that means quicker access to cutting-edge treatments. For the research community, it means a more streamlined path to innovation.

How regenold UK Can Help

As these reforms come into force, early engagement with regulators and proactive trial planning will be key to making the most of the UK's evolving clinical research landscape. Sponsors, researchers, and developers should consider how these changes can be integrated into their clinical development strategies to accelerate timelines while maintaining high standards of patient safety.

If you're looking to strengthen your clinical development narrative, build confidence with regulators and partners, or maximise the impact of your research, our team is ready to support you.